Sino Biopharmaceutical (HK:1177) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Sino Biopharmaceutical has received approval from China’s National Medical Products Administration for its Benmelstobart Injection, in combination with Anlotinib Hydrochloride Capsule, to treat recurrent or metastatic endometrial cancer. This marks the second approval for Benmelstobart and the seventh for Anlotinib, highlighting significant potential in addressing unmet needs for patients with limited treatment options. The company’s commitment to advancing innovative therapies continues with ongoing Phase III trials for various cancers.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
